Guantao Advised Cellular Biomedicine on Public offering of Its Common Stock-赌博网站

Guantao Advised Cellular Biomedicine on Public offering of Its Common Stock

2019-04-01

HOME > Guantao News > Deals > Guantao Advised Cellular Biomedicine on Public offering of Its Common Stock

Guantao Advised Cellular Biomedicine on Public offering of Its Common Stock

Eastern Time (US & Canada) March 25, 2019, Cellular Biomedicine Group Inc. (Nasdaq: CBMG) successfully closed an underwritten public offering of its common stock (“Offering”).

Cantor Fitzgerald & Co. and Robert W. Baird & Co. Incorporated served as joint book-running managers and underwriters for the Offering. Guantao acted as the legal adviser to both underwriters in relation to the laws of People’s Republic of China.

Cellular Biomedicine Group, Inc. listed on The Nasdaq Global Market is a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases.

Guantao team was led by Hong Kong office managing partner Grace Pengpeng YAN and Yan RONG.

2025·09·18

Guantao Advises Huayan Cheng on Its Increased Acquisition of Shares in Huacheng Industrial Control Co., Ltd. (Stock Code: 873553)

2025·08·08

Guantao Deals │Guantao Advises Tosso, an AI-Powered Robotic Sanding and Polishing Company, on Its Series A Financing

2025·07·30

Guantao Deals | Guantao to assist PetroChina Kunlun Capital and other investors in the capital increase of China Fusion Energy Co., Ltd.

2025·07·29

Guantao Deals | Guantao Advises CNPC Taihu Investment on Its Capital Increase in State Grid Xinyuan Holdings

亚洲最大赌博网站